Celldex Therapeutics to Present New Clinical and Preclinical Data at the AACR Annual Meeting 2016

HAMPTON, N.J., March 17, 2016 (GLOBE NEWSWIRE) -- Celldex Therapeutics, Inc. (NASDAQ: CLDX) announced today that the Company and its collaborating investigators will present seven posters with new clinical and preclinical data at the American Association for Cancer Research (AACR) Annual Meeting 2016 in New Orleans.

Highlights include immune response data from the ongoing Phase 1/2 study of varlilumab and nivolumab in multiple solid tumors, the role of gpNMB as a relevant therapeutic target across multiple cancers and a late-breaking poster from the Phase 1 investigator-sponsored study of CDX-301 (Flt3L) in B-cell lymphomas.

The following Celldex-sponsored abstracts have been selected for poster presentations at AACR:

• Title: Phase 1 results from the combination of an immune-activating anti-CD27 antibody (varlilumab) in combination with PD-1 blockade (nivolumab): activation across multiple immune pathways without untoward immune-related adverse events Date/Time: Monday, April 18, 8:00 a.m. – 12:00 p.m. CDT Location: Section 13 Abstract: CT023
• Title: Glycoprotein NMB (gpNMB) overexpression is prevalent in human cancers: pancreatic cancer, non-small cell lung cancer, head and neck cancer, and osteosarcoma Date/Time: Wednesday, April 20, 8:00 a.m. – 12:00 p.m. CDT Location: Section 27 Abstract: 5032 
• Title: IHC and RT-PCR assays for detection of cancer antigen NY-ESO-1 in human tissues Date/Time: Monday, April 18, 8:00 a.m. – 12:00 p.m. CDT Location: Section 21 Abstract: 1373 
• Title: Development and characterization of novel CD40 antibody agonists for cancer immunotherapy Date/Time: Wednesday, April 20, 8:00 a.m. – 12:00 p.m. CDT Location: Section 22 Abstract: 4866

             The following investigator-sponsored abstracts have been selected for poster presentations at AACR:

• Title: In situ vaccination of low-grade lymphoma with intratumoral Flt3L and poly-ICLC with low-dose radiotherapyDate/Time: Monday, April 18, 8:00 a.m. – 12:00 p.m. CDTLocation: Section 10Abstract: LB-081

• Title: Targeting GPNMB with 89Zr-CR011 for PET imaging of triple negative breast cancer Date/Time: Tuesday, April 19, 1:00 p.m. – 5:00 p.m. CDT Location: Section 33 Abstract: 4209 
• Title: Targeting the melanosome: overcoming MAPK-inhibitor resistance in melanomaDate/Time: Sunday, April 17, 1:00 p.m. – 5:00 p.m. CDTLocation: Section 16Abstract: 296

About Celldex Therapeutics, Inc.

Celldex is developing targeted therapeutics to address devastating diseases for which available treatments are inadequate. Our pipeline is built from a proprietary portfolio of antibodies and immunomodulators used alone and in strategic combinations to create novel, disease-specific therapies that induce, enhance or suppress the body's immune response. Visit www.celldex.com.

 

Contact:
Sarah Cavanaugh
Vice President of Investor Relations & Corp Communications
Celldex Therapeutics, Inc.
(781) 433-3161
[email protected]

Charles Liles
Manager of Investor Relations & Corp Communications
Celldex Therapeutics, Inc.
(781) 433-3107
[email protected]

Media Contact:

Dan Budwick
Pure Communications, Inc.
(973) 271-6085
[email protected]

Source: Celldex Therapeutics, Inc.

---

Serious News for Serious Traders! Try StreetInsider.com Premium Free!

---

You May Also Be Interested In

• Celldex (CLDX) Announces Completion of Enrollment in Phase 2 Study of Barzolvolimab in Patients with Chronic Inducible Urticaria
• UPDATE: LifeWallet Announces a Comprehensive Settlement with a Group of Affiliated Property & Casualty Insurers 
• Pioneering Nuclear Technology Firm, Curio, Closes $14 Million Seed Round to Drive Clean Energy Innovation